[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531912":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":55,"collaborators":26,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":26,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":26,"overallStatus":78,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Szent Miklós Szolgálat Kft.","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Probiotics","ACTIVE_COMPARATOR","Study product containing L. reuteri (PTA5289 and DSM 17938) taken orally once in the morning and once in the evening, each time 5 drops.",[13],"Dietary Supplement: BioGaia Pharax (L. reuteri PTA 5289 and DSM 17938)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo taken orally once in the morning and once in the evening, each time 5 drops.",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","BioGaia Pharax (L. reuteri PTA 5289 and DSM 17938)","BioGaia Pharax drops (with PTA5289 and DSM 17938) with vitamin D3 will be manufactured and delivered by BioGaia AB as oil suspension.",[9],null,{"type":6,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Placebo product contains vitamin D3 and is identical to the active product but lacks L. reuteri.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Gergely Milosevits, MD, PhD","CONTACT","+36308425722","drgergelymilosevits@gmail.com",[37],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Szigetszentmiklós","Pest County","2310","Hungary","HU",{"type":45,"coordinates":46},"Point",[47,48],19.04335,47.34382,{"lat":48,"lon":47},[51,53],{"name":52,"role":33,"phone":34,"phoneExt":26,"email":35},"Gergely Milosevits, M.D., PhD.",{"name":52,"role":54,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Milosevits Gergely","Principal Investigator","100531912","a-study-to-investigate-the-effect-of-probiotics-l-reuteri-atcc-pta-5289-and-l-reuteri-dsm-17938-on-symptoms-of-viral-upper-respiratory-tract-infections-in-children-100531912",false,"NCT06205966","A Study to Investigate the Effect of Probiotics (L. Reuteri ATCC PTA 5289 and L. Reuteri DSM 17938) on Symptoms of Viral Upper Respiratory Tract Infections in Children","A Randomized, Double Blind, Placebo-controlled Study to Investigate the Effect of Probiotics (L. Reuteri ATCC PTA 5289 and L. Reuteri DSM 17938) on Symptoms of Viral Upper Respiratory Tract Infections in Children","Inclusion Criteria:\n\n* Children with symptoms of upper respiratory tract infection (coughing\u002Ffever\u002Fsneezing\u002Frunny or congested nose\u002Fpharynx pain)\n* Any gender\n* Age from 4 years to 17 years\n* Signing a informed consent form by at least one parent, foster parent or guardian after patient information and by children aged over 6 years\n* Negative Strep test\n\nExclusion Criteria:\n\n* Use of antibiotics or probiotics in the 10 days prior to study enrolment\n* Use of a probiotic other than the test sample during the study\n* Eight or more otitis media within 12 months\n* Two or more bacterial sinusitis within 12 months\n* Two or more pneumonia episodes within 12 months\n* History of two or more invasive infections (meningitis, cellulitis, osteomyelitis, septicaemia)\n* Chronic diarrhea\n* Recurrent deep skin or organ abscesses\n* Persistent superficial candidiasis\n* Use of antibiotics for two months or more to treat respiratory infections within 12 months\n* Gastroesophageal reflux\n* Perennial (e.g., dust mite or mold) or current seasonal hay fever allergy\n* Primary or secondary ciliary dyskinesia\n* Congenital malformations of the respiratory tract","ALL","4 Years","17 Years",{"count":70,"type":71},142,"ESTIMATED","INTERVENTIONAL",[74],"NA","This study investigates the effect of Lactobacillus reuteri probiotic strains (ATCC PTA 5289 and DSM 17938) on symptoms of viral upper-respiratory tract infections in children.",[77],"Virus Diseases in Children","UNKNOWN","2024-01-11",{"date":81,"type":82},"2024-01-16","ACTUAL",{"date":84,"type":82},"2023-12-21",{"date":86,"type":71},"2025-11-30",{"name":57,"class":6},1]